Skip to main content
Erschienen in: Herz 6/2018

23.08.2017 | Review articles

Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease

A meta-analysis

verfasst von: X. Hu, J. Shang, W. Yuan, S. Zhang, Y. Jiang, B. Zhao, Y. Duan, J. Xiao, Z. Zhao

Erschienen in: Herz | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Paricalcitol, a selective activator of the vitamin D receptor (VDR), influences calcium and phosphorus homeostasis and bone metabolism. Whether paricalcitol reduces cardiovascular risk and protects renal function remains unclear. To systematically evaluate this in patients with chronic kidney disease (CKD), we conducted a meta-analysis of published randomized controlled trials (RCTs).

Methods

We searched MEDLINE, Embase, the Cochrane Library, and reference lists for RCTs comparing paricalcitol with placebo in stage 2–5 CKD (including pre-dialysis and renal replacement patients). The Cochrane quality assessment method was used to evaluate study quality. Results were summarized as risk ratios (RRs) for dichotomous outcomes or mean differences (MD) for continuous outcomes.

Results

We included 21 studies comprising 1894 patients. Compared to placebo, paricalcitol reduced the risk of cardiovascular events (RR 0.55; 95% CI 0.35–0.87; p = 0.01), but the RR of hypercalcemia associated with paricalcitol was 6.50 (95% CI 3.21–13.15; p < 0.00001). Paricalcitol cannot significantly change systolic blood pressure and cardiac structure. Although proteinuria reduction was achieved more frequently with paricalcitol (RR 1.51; 95% CI 1.25–1.82; p < 0.0001), it did not significantly reduce proteinuria level compared to placebo. Paricalcitol could not protect renal function to delay CKD progression, since it reduced the glomerular filtration rate (MD −3.15; 95% CI −4.35–−1.96; p < 0.0001) and elevated serum creatinine (MD 0.93; 95% CI 0.10–0.68; p = 0.008).

Conclusion

Paricalcitol reduces the risk of cardiovascular events in CKD patients but increases the risk of hypercalcemia and cannot improve cardiac structure. Meanwhile, it cannot significantly reduce proteinuria level or protect renal function.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gouni-Berthold I, Krone W, Berthold HK (2009) Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 7:414–422CrossRef Gouni-Berthold I, Krone W, Berthold HK (2009) Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 7:414–422CrossRef
2.
Zurück zum Zitat Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139–156CrossRef Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139–156CrossRef
3.
Zurück zum Zitat Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M (2012) Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 60:567–575CrossRef Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M (2012) Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 60:567–575CrossRef
4.
Zurück zum Zitat Webb AR (2006) Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92:17–25CrossRef Webb AR (2006) Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92:17–25CrossRef
5.
Zurück zum Zitat Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH (2010) Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 65:225–236CrossRef Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH (2010) Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 65:225–236CrossRef
6.
Zurück zum Zitat Zheng Z, Shi H, Jia J, Li D, Lin S (2013) Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 14:199CrossRef Zheng Z, Shi H, Jia J, Li D, Lin S (2013) Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 14:199CrossRef
7.
8.
Zurück zum Zitat Finch JL, Brown AJ, Slatopolsky E (1999) Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980–985PubMed Finch JL, Brown AJ, Slatopolsky E (1999) Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980–985PubMed
9.
Zurück zum Zitat Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32:S40–S47CrossRef Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32:S40–S47CrossRef
10.
Zurück zum Zitat Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRef Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRef
11.
Zurück zum Zitat Cheng J, Zhang W, Zhang X, Li X, Chen J (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391–400CrossRef Cheng J, Zhang W, Zhang X, Li X, Chen J (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391–400CrossRef
12.
Zurück zum Zitat Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L (2013) Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int 2013:320560PubMed Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L (2013) Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int 2013:320560PubMed
13.
Zurück zum Zitat Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823–2828CrossRef Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823–2828CrossRef
14.
Zurück zum Zitat Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249–255CrossRef Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249–255CrossRef
15.
Zurück zum Zitat Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263–276CrossRef Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263–276CrossRef
16.
Zurück zum Zitat De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int 83:323–330CrossRef De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney Int 83:323–330CrossRef
17.
Zurück zum Zitat De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551CrossRef De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551CrossRef
19.
Zurück zum Zitat Joergensen C, Tarnow L, Goetze JP, Rossing P (2015) Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabet Med 32:374–381CrossRef Joergensen C, Tarnow L, Goetze JP, Rossing P (2015) Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabet Med 32:374–381CrossRef
21.
Zurück zum Zitat Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R (2012) Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 164(6):902–909.e2. doi:10.1016/j.ahj.2012.09.018 CrossRefPubMed Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R (2012) Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 164(6):902–909.e2. doi:10.​1016/​j.​ahj.​2012.​09.​018 CrossRefPubMed
22.
Zurück zum Zitat Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674–684. doi:10.1001/jama.2012.120 CrossRefPubMed Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674–684. doi:10.​1001/​jama.​2012.​120 CrossRefPubMed
23.
Zurück zum Zitat Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA (2015) Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. J Diabetes Complicat 29:433–437CrossRef Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA (2015) Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. J Diabetes Complicat 29:433–437CrossRef
24.
Zurück zum Zitat Wang AYM, Fang F, Chan J, Wen YY, Qing S, Chan IHS, Lo G, Lai KN, Lo WK, Lam CWK, Yu CM (2014) Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial. J Am Soc Nephrol 25:175–186CrossRef Wang AYM, Fang F, Chan J, Wen YY, Qing S, Chan IHS, Lo G, Lai KN, Lo WK, Lam CWK, Yu CM (2014) Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial. J Am Soc Nephrol 25:175–186CrossRef
25.
Zurück zum Zitat Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F (2014) Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64(5):1005–1011. doi:10.1161/hypertensionaha.114.03748 CrossRefPubMed Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F (2014) Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64(5):1005–1011. doi:10.​1161/​hypertensionaha.​114.​03748 CrossRefPubMed
26.
Zurück zum Zitat Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, Heilman RL, Mazur MJ, Hamawi K, Larson TS, Kumar R (2013) Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 13(6):1576–1585. doi:10.1111/ajt.12227 CrossRefPubMed Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, Heilman RL, Mazur MJ, Hamawi K, Larson TS, Kumar R (2013) Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 13(6):1576–1585. doi:10.​1111/​ajt.​12227 CrossRefPubMed
27.
Zurück zum Zitat Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49:814–823CrossRef Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49:814–823CrossRef
28.
Zurück zum Zitat Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48–S54CrossRef Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48–S54CrossRef
29.
Zurück zum Zitat Lundwall K, Jorneskog G, Jacobson SH, Spaak J (2015) Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol 42:265–273CrossRef Lundwall K, Jorneskog G, Jacobson SH, Spaak J (2015) Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol 42:265–273CrossRef
30.
Zurück zum Zitat Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD (2001) A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 38:792–802CrossRef Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD (2001) A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 38:792–802CrossRef
31.
Zurück zum Zitat Perez V, Sanchez A, Bayes B, Navarro-Munoz M, Lauzurica R, Pastor MC, Romero R (2010) Effect of paricalcitol on the urinary peptidome of kidney transplant patients. Transplant Proc 42:2924–2927CrossRef Perez V, Sanchez A, Bayes B, Navarro-Munoz M, Lauzurica R, Pastor MC, Romero R (2010) Effect of paricalcitol on the urinary peptidome of kidney transplant patients. Transplant Proc 42:2924–2927CrossRef
32.
Zurück zum Zitat Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM (2008) Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28:97–106CrossRef Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM (2008) Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28:97–106CrossRef
33.
Zurück zum Zitat Trillini M, Cortinovis M, Ruggenenti P, Loaeza JR, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N (2015) Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 26:1205–1214CrossRef Trillini M, Cortinovis M, Ruggenenti P, Loaeza JR, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N (2015) Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 26:1205–1214CrossRef
34.
Zurück zum Zitat Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238CrossRef Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238CrossRef
35.
Zurück zum Zitat Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265CrossRef Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257–265CrossRef
36.
Zurück zum Zitat Geleijnse JM (2011) Vitamin D and the prevention of hypertension and cardiovascular diseases: a review of the current evidence. Am J Hypertens 24:253–262CrossRef Geleijnse JM (2011) Vitamin D and the prevention of hypertension and cardiovascular diseases: a review of the current evidence. Am J Hypertens 24:253–262CrossRef
37.
Zurück zum Zitat Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRef Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRef
38.
Zurück zum Zitat Li XH, Feng L, Yang ZH, Liao YH (2015) The effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology (Carlton) 20(10):706–714. doi:10.1111/nep.12505 CrossRef Li XH, Feng L, Yang ZH, Liao YH (2015) The effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology (Carlton) 20(10):706–714. doi:10.​1111/​nep.​12505 CrossRef
39.
Zurück zum Zitat Schmitz KJ, Skinner HG, Bautista LE, Fingerlin TE, Langefeld CD, Hicks PJ, Haffner SM, Bryer-Ash M, Wagenknecht LE, Bowden DW, Norris JM, Engelman CD (2009) Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 22:867–870CrossRef Schmitz KJ, Skinner HG, Bautista LE, Fingerlin TE, Langefeld CD, Hicks PJ, Haffner SM, Bryer-Ash M, Wagenknecht LE, Bowden DW, Norris JM, Engelman CD (2009) Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 22:867–870CrossRef
40.
Zurück zum Zitat Kunutsor SK, Burgess S, Munroe PB, Khan H (2014) Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol 29:1–14CrossRef Kunutsor SK, Burgess S, Munroe PB, Khan H (2014) Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol 29:1–14CrossRef
41.
Zurück zum Zitat Lee JH, O’keefe JH, Bell D, Hensrud DD, Holick MF (2008) Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52:1949–1956CrossRef Lee JH, O’keefe JH, Bell D, Hensrud DD, Holick MF (2008) Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 52:1949–1956CrossRef
42.
Zurück zum Zitat Boucher BJ, John WG, Noonan K (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 80:1666 (author reply 1666–1667)CrossRef Boucher BJ, John WG, Noonan K (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 80:1666 (author reply 1666–1667)CrossRef
43.
Zurück zum Zitat Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320–325CrossRef Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320–325CrossRef
44.
Zurück zum Zitat Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103:521–524CrossRef Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103:521–524CrossRef
45.
Zurück zum Zitat Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394–1402CrossRef Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394–1402CrossRef
46.
Zurück zum Zitat Tan X, Li Y, Liu Y (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17:3382–3393CrossRef Tan X, Li Y, Liu Y (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17:3382–3393CrossRef
47.
Zurück zum Zitat Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741–1752CrossRef Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741–1752CrossRef
48.
Zurück zum Zitat De Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ (2013) Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 24:1863–1871CrossRef De Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ (2013) Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 24:1863–1871CrossRef
Metadaten
Titel
Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease
A meta-analysis
verfasst von
X. Hu
J. Shang
W. Yuan
S. Zhang
Y. Jiang
B. Zhao
Y. Duan
J. Xiao
Z. Zhao
Publikationsdatum
23.08.2017
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 6/2018
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-017-4605-y

Weitere Artikel der Ausgabe 6/2018

Herz 6/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.